


## *Sex differences in the psychopharmacological treatment of depression*

John J. Sramek, PharmD; Michael F. Murphy, MD, PhD;  
Neal R. Cutler, MD



*Although a number of studies have observed that females respond better to serotonergic antidepressants than males and that postmenopausal females have a diminished response to antidepressants compared with younger females, there are also studies that conflict with both of these findings, making any generalizations regarding sex differences difficult to make. Sex variance in antidepressant efficacy and pharmacokinetics profiles have been attributed to sex-based physiological differences, behavioral differences, related disorders, and sex-specific conditions, including pregnancy and menopause. This paper will review the history and current research on sex effects of antidepressant treatment.*

© 2016, AICH – Servier Research Group

*Dialogues Clin Neurosci.* 2016;18:447-457.

**Keywords:** antidepressant; depression; efficacy; estrogen; hormone; menopause; pharmacokinetics; sex; SSRI

**Author affiliations:** Worldwide Clinical Trials, Beverly Hills, California, USA (John J. Sramek, Neal R. Cutler); Worldwide Clinical Trials, King of Prussia, Pennsylvania, USA (Michael F. Murphy)

**Address for correspondence:** Neal R. Cutler, MD, Worldwide Clinical Trials, 401 N. Maple Drive, Beverly Hills, California 90210, USA (email: neal.cutler@worldwide.com)

### Introduction

There is extensive literature on the topic of sex differences in antidepressant treatment.<sup>1</sup> Sex differences in antidepressant efficacy have been linked to sex-related physiological differences, behavioral characteristics, comorbid diseases, menopause, pregnancy, and adherence, among other factors. Although conclusions are tempered by the variability existing in levels and durations of exposure to antidepressants, these data do provide a spectrum of intrinsic factors that are considered to be prognostically important. For example, variance in body fat, hormone levels, and liver metabolism between sexes have been shown to affect the pharmacokinetics of a drug when orally administered. Sex-specific factors have been identified in the clinical presentation, prevalence, and resiliency of depression. This paper will review the clinical literature and research on sex-related differences in the efficacy and pharmacokinetics of antidepressants, including female-specific variables, and how these differences can affect the outcome of antidepressant treatment.

### Sex differences in the pathogenesis of depression

The incidence of depression in women is nearly double that in men.<sup>2,3</sup> This is independent of diagnostic nomenclature, including atypical depression, unipolar depression, dysthymia, and seasonal affective disorder.<sup>4-6</sup> These

# Pharmacological aspects

differences have been found across all age groups.<sup>7</sup> The lifetime risk of major depression in the United States is 21% in females versus 13% in males.<sup>8</sup> Symptom presentation is generally more severe in women. Depressed females typically experience prolonged or recurrent depression more than depressed males, with a younger onset age and lower quality of life.<sup>9</sup> Depressed females generally experience greater weight gain, anxiety, and physical manifestations of their disease than depressed men.<sup>10-13</sup>

The causes of these differences in clinical presentation and response to pharmacotherapy between sexes are unknown, but several theories exist. Sex differences in the incidence of depression generally materialize during adolescence, which has led to suggestions that female susceptibility may be linked to surges in reproductive hormones (estrogen and progesterone) during puberty.<sup>14</sup> The incidence of depression in women after menopause (when reproductive hormones stabilize) appears to be similar to that in men.<sup>15</sup> Levels of estradiol (E2) have also been reported to be lowered in depressed premenopausal and perimenopausal women.<sup>16,17</sup> Estrogen and serotonin appear to interact in significant ways. In animals, estrogen induces changes in brain serotonin transmission, binding, and metabolism.<sup>18</sup>

Sex-related differences in the prevalence of depression may also be affected by differential monoamine functioning between sexes. Monoamine tryptophan depletion results in a temporary decrease in serotonin transmission, and this increased depressive symptoms in females significantly more than males.<sup>19</sup> Likewise, positron emission tomography (PET) demonstrated decreased serotonin synthesis in females compared with males after tryptophan was depleted.<sup>20</sup> Elevated levels of serotonin, as well as the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), were found in women compared with men,<sup>21</sup> which may be related to a greater availability of the serotonin transporter in females.<sup>22</sup> The serotonin 5-HT<sub>1A</sub> receptor subtype demonstrates decreased binding potential with age in men but not in women, and this receptor subtype is associated with depression pathogenesis.<sup>23</sup> Brain levels of serotonin and norepinephrine show greater age-related changes in females than in males.<sup>24</sup> A study of 75 healthy volunteers of different ages (21 to 80) and sexes (40 females, 35 males) found platelet monoamine oxidase manifested a significant increase in females compared with males ( $P < 0.05$ ).<sup>25</sup> The dopaminergic system may

also be involved in depression pathology. Through neuroimaging studies, women have been shown to possess a higher concentration of synaptic dopamine in the striatum than men do, and age decreases synaptic dopamine levels in men more than women.<sup>26</sup> Additionally, female hormones seem to increase the turnover rate of presynaptic dopamine in preclinical investigations.<sup>27,28</sup> Women show a greater reduction in striatal dopamine release in response to amphetamines than men.<sup>29</sup> Thus, across monoaminergic systems implicated in the pathogenesis of depression (serotonin, dopamine, and norepinephrine), there is suggestive evidence both in preclinical and clinical studies in support of a pathophysiological basis for differential presentation and response based upon sex.

## Sex differences in response to antidepressants

There is still no clear consensus on whether there are sex-related efficacy differences in antidepressant treatment, despite decades of research on this topic. Part of this lack of consensus is related to the diverse diagnostic and trial methodology that has been employed across studies, introducing significant confounds in interpretation. Studies have shown sex differences in antidepressant efficacy while attempting to accommodate differences in medication, dose, regimen, and compliance (see *Table I* for a list of factors that may contribute to sex differences in antidepressant efficacy). See *Table II*<sup>30-38</sup> for a list of studies where females respond better to antidepressants than males and *Table III*<sup>10,31,39-41</sup> for a list of studies where

Body fat and weight distribution
Liver metabolism rates
Changes in physiology and hormone levels during puberty, menstruation, and menopause
Gastric emptying, acid production, and splanchnic blood flow
Plasma volume, protein levels, and enzyme activity
Drug transport and clearance rates
Adherence
Side-effect profile differences
Interactions between estrogen and serotonin in the brain
Brain monoamine functioning

**Table I.** Factors that may contribute to sex differences in antidepressant efficacy.

males respond better to antidepressants than females. A significantly greater therapeutic response has been shown for males than females for the tricyclic antidepressant (TCA) imipramine.<sup>10,31,40,41</sup> These differences existed even when possible differences in antidepressant type and use patterns, including compliance, were considered.

A number of studies suggest women may respond better to selective serotonin reuptake inhibitors (SSRIs) than men,<sup>30,31,34,35,37,38,42</sup> although the results of one

of these studies has been disputed.<sup>43</sup> The greater efficacy results for females than males (studies cited in *Table II*<sup>30-38</sup>) remain variable. For example, examining several of the more recent studies, which employed the HAM-D (Hamilton Depression Rating Scale) as the primary efficacy assessment for SSRI treatment, females had a 15%, 23%, and 40% greater improvement than males.<sup>31,34,35</sup> Younger females exposed to the SSRI fluvoxamine showed greater response than males and older females as well (>44 years old).<sup>36</sup> In a naturalistic

Reference	Drug type	Study type	Subjects	Results
Haykal and Akiskal, <sup>30</sup> 1999	SSRIs, TCAs	TCA-type antidepressants or fluoxetine	25 Male and 17 female primary dysthymic patients	Females responded better than males to SSRIs
Kornstein et al, <sup>31</sup> 2000	SSRIs, TCAs	12-Wk double-blind trial with sertraline or imipramine	235 Male and 400 female outpatients with chronic major depression or double depression	Females responded better to SSRI sertraline; differences observed primarily in premenopausal females
Martenyi et al, <sup>32</sup> 2001	SSRIs, TCAs	6-Wk, double-blind trial of SSRI (fluoxetine) and a norepinephrinergic TCA (maprotiline)	105 Male and female depressed patients	Females in their reproductive period were more responsive to SSRIs than norepinephrinergic TCAs
Quitkin et al, <sup>33</sup> 2002	TCAs, MAOIs, SSRIs	20-Y review of 8 placebo-controlled antidepressant trials and 1 open-label study	1746 Depressed patients aged between 18 and 65 y	Older females had superior response to TCAs than younger females; females had statistically superior response to MAOIs than males
Khan et al, <sup>34</sup> 2005	SSRIs, SNRIs	Review of 15 randomized, placebo-controlled trials for sex differences in antidepressant efficacy	323 Depressed patients	Females had a significantly greater response than males to SSRI and (to a lesser extent) SNRI treatment
Berlanga and Flores-Ramos, <sup>35</sup> 2006	SSRIs, SNRIs	8-Wk, double-blind clinical trial for sex differences with SSRI citalopram and SNRI reboxetine	86 Depressed patients (48 females, 38 males) aged 18 to 40 y	Premenopausal females responded better than males to serotonergic antidepressants
Naito et al, <sup>36</sup> 2007	SSRIs, SNRIs	6-Wk study of the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients	103 Patients with MDD (66 females, 37 males)	Fluvoxamine was more effective in younger female patients than older female patients and male patients
Young et al, <sup>37</sup> 2009	SSRI	12- to 14-Wk study of citalopram	1043 Male and 1833 female patients with single or recurrent non-psychotic MDD	Females had a better response to the SSRI citalopram than males
Yang et al, <sup>38</sup> 2011	Variety of antidepressants	12-Wk naturalistic study	723 Depressive patients (535 females, 188 males)	Females had a better response to antidepressant treatment than males

**Table II.** Studies finding greater antidepressant efficacy in females than in males.

# Pharmacological aspects

study of 138 depressed patients, Vermeiden et al reported a differential sex response based on the antidepressant used; males responded significantly better to imipramine than premenopausal females, but the females responded better to fluvoxamine than the males.<sup>44</sup> An atypical depression study produced mixed findings: whereas monoamine oxidase inhibitors (MAOIs) demonstrated superiority over TCAs in females, the opposite was true in males.<sup>45</sup>

On the other hand, many studies have not detected sex differences in the efficacy of antidepressants (see *Table IV*<sup>33,42,46-55</sup>). The serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine and SSRIs were both shown to produce comparable responses in males and females.<sup>47</sup> Likewise, TCAs, MAOIs, and the SSRI fluoxetine showed no sex differences in drug efficacy in a large, retrospective study.<sup>33</sup> Other studies have shown females do not respond preferentially to SSRIs,<sup>51</sup> nor do males respond preferentially to TCAs.<sup>49</sup> Furthermore, Hildebrandt et al showed no sex effect on the efficacy of the TCA clomipramine, the SSRIs citalopram and paroxetine, and the MAOI moclobemide.<sup>48</sup>

Meta-analyses perform a service by aggregating clinical trial data into an analysis that may help resolve inconsistent conclusions. A meta-analysis of 30 randomized placebo-controlled trials of imipramine or amitriptyline as an example found no effect of sex

on TCA efficacy.<sup>50</sup> A more compelling comprehensive analysis using contemporaneous techniques created an “individual patient data” meta-analysis with the primary data of 1766 patients from 14 eligible randomized trials, comparing cognitive behavior therapy (CBT) with pharmacotherapy, and comparing either CBT or pharmacotherapy with pill placebo. This study is additionally noteworthy in that pharmacotherapy, as well as other recognized therapeutic modalities such as CBT, were examined. No sex-modulating effects on treatment were detected regardless of therapeutic intervention.<sup>55</sup> A 2010 analysis by Kornstein et al pooled nine clinical trials of outpatients aged 18 years or older with major depressive disorder (MDD; 1108 males and 1805 females) who received desvenlafaxine or placebo for 8 weeks. They found that desvenlafaxine generally improved depressive symptoms regardless of sex.<sup>53</sup> In 2014, Kornstein et al performed a secondary analysis of a multiphase, multicenter, double-blind study in which adult outpatients (670 females and 377 males) with recurrent MDD were randomly assigned to 10 weeks of acute phase venlafaxine extended release or fluoxetine. They found no observed sex difference in the response to treatment.<sup>54</sup>

Although no definite explanation exists for the many contradictions in this data, numerous issues of methodology might offer a rationale. Such differences

Reference	Drug type	Study type	Subjects	Results
Kornstein et al, <sup>31</sup> 2000	SSRIs, TCAs	12-Wk double-blind trial with sertraline or imipramine	235 Male and 400 female outpatients with chronic major depression or double depression	Males responded better to TCA imipramine than females
Hamilton et al, <sup>39</sup> 1996	TCAs	Meta-analysis of 35 studies that reported imipramine response rates	342 Males and 711 females with depression	Imipramine response rates were significantly better for males than females
Old Age Depression Interest Group, <sup>40</sup> 1993	TCAs	24-Mo, double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin	19 Males and 50 females with major depression	Males taking dothiepin were less likely to experience a recurrence of depression than females
Frank et al, <sup>10</sup> 1988	TCAs	16-Wk trial with imipramine and interpersonal psychotherapy	50 Males and 180 females with recurrent major depression	Males showed a more rapid and sustained clinical response to imipramine than females
Raskin, <sup>41</sup> 1974	TCAs and MAOIs	3-Wk trial with chlorpromazine, imipramine, diazepam, phenelzine, or placebo	268 Males and 612 females with moderate depression	Older males responded more positively to active drug than older females

**Table III.** Studies finding greater antidepressant efficacy in males than in females.

may arise between demographics or due to the nature of diagnostic nosology, class of therapeutic agent, and various parameters related to amount, regimen, and duration of exposure. Additionally, the criteria for determining a significant response to treatment varied considerably between studies. One study used a paired

Reference	Drug type	Study type	Subjects	Results
Himmelhoch et al, <sup>46</sup> 1991	MAOIs, TCAs	Controlled, double-blind comparison: tranylcypromine vs imipramine	56 Outpatients who met operationalized criteria for anergic bipolar depression	Males and females responded comparably to both drugs
Entsuaeh et al, <sup>47</sup> 2001	SSRIs, SNRIs	Meta-analysis of 8 comparable double-blind, active-controlled, randomized SSRI or venlafaxine clinical trials	2045 Patients with major depression or MDD, aged 18-83 y	Males and females have comparable responses to SSRIs and SNRIs across various age groups
Quitkin et al, <sup>33</sup> 2002	SSRIs, TCAs, MAOIs	Retrospective analysis of patients treated with TCAs, MAOIs, fluoxetine, or placebo	1746 Depressed patients aged 18-65 y	No sex- or menopausal status-based difference in drug efficacy
Hildebrandt et al, <sup>48</sup> 2003	SSRIs, TCAs, MAOIs	Review of 3 Danish double-blind randomized, controlled trials	292 Inpatients (96 males, 196 females) with major and predominantly melancholic depression	No relationship between plasma concentrations, sex, and therapeutic outcome
Parker et al, <sup>49</sup> 2003	SSRIs, TCAs	Review of retrospective and prospective naturalistic uncontrolled studies	Patients with melancholic and nonmelancholic depression	No sex difference in response to either drug class
Baca et al, <sup>42</sup> 2004	SSRIs, TCAs	8-Wk, multicenter, randomized, open-label, parallel group comparative trial of sertraline vs imipramine	234 Patients with major depression or dysthymia (50 males, 184 females)	Overall, statistically significant differences in effectiveness between men and women were not found
Wohlfarth et al, <sup>50</sup> 2004	TCAs	Review of 30 randomized, placebo-controlled trials of antidepressant efficacy	3886 Patients (1555 males, 2331 females) with depression	TCA response is independent of sex
Thiels et al, <sup>51</sup> 2005	SSRIs	Review of data from a 6-mo prospective sertraline utilization observation study	1594 Male and 3858 female depressed patients	No sex difference in side-effects, treatment termination, or treatment response to SSRI
Pinto-Meza et al, <sup>52</sup> 2006	SSRIs	6-Mo follow-up study of antidepressant treatment with a SSRI (citalopram, fluoxetine, paroxetine, or sertraline)	242 Females (95 in menopause) and 59 males with major depression	No sex differences were observed in treatment response, depression severity, and symptomatology
Kornstein et al, <sup>53</sup> 2010	SNRIs	Review of 9 studies comparing desvenlafaxine or placebo for 8 weeks	2913 Outpatients (1108 males, 1805 females) with MDD	Desvenlafaxine generally improved depressive symptoms across sex subgroups
Kornstein et al, <sup>54</sup> 2014	SSRIs, SNRIs	Follow-up review of a 2-y study of acute-phase venlafaxine extended release or fluoxetine	670 Female (168 in menopause) and 377 male outpatients with recurrent MDD	No sex differences were observed in treatment response
Cuijpers et al, <sup>55</sup> 2014	SSRIs, TCAs, other antidepressants	Meta-analysis of 14 eligible randomized trials comparing CBT with pharm, and comparing CBT or pharm with pill placebo	1202 females and 564 males with depression, subjects from 14 eligible randomized trials	No sex differences were observed in treatment response

**Table IV.** Studies finding no sex-based efficacy differences with antidepressants.



# Pharmacological aspects

*t*-test to compare total HAM-D17 (17-item HAM-D) baseline scores with scores after treatment,<sup>32</sup> equating differences on this parameter as potentially clinically important provided they were statistically significant. Another study declared a clinically significant response after a 50% or greater decrease in HAM-D21 (21-item HAM-D) scores.<sup>47</sup> Age variation between female patients in these studies may also influence their outcomes, as levels of female sex hormones change with age and menopause and may affect the efficacy and metabolism of antidepressants. More potential variables include clinical presentation (ie, typical versus atypical), previous antidepressant treatment, differing drugs and dosages, patient adherence to treatment plans, and the type of study conducted (prospective or meta-analysis of large data pools).

Side effects of antidepressants can also detract from overall efficacy, particularly if they lead to early discontinuation. Most of the literature reviewed above regarding sex differences in antidepressant efficacy fail to take adverse events into account. Deleterious effects on sexual drive and satisfaction, but sometimes improvement, have been reported in women taking SSRIs, and weight gain may be more problematic in women because of societal expectations, but further research needs to be done in this area to determine whether true sex differences exist.<sup>56</sup> One study found depressed females to have greater sexual dysfunction than depressed males, yet female sexual dysfunction actually improved with SSRI treatment, whereas male sexual dysfunction worsened with the same treatment.<sup>57</sup> The improvement in sexual function for females may be due to the fact that any negative sexual side effects of SSRIs in women are overshadowed by the drug's positive effects on ameliorating depressive symptoms. As various antidepressants have different adverse event profiles, the clinician can switch to another class of antidepressant if such side effects prove problematic.<sup>58</sup> For example, Shen and Hsu recommended bupropion as an appropriate substitution for SSRIs in patients looking to reduce sexual side effects caused by their antidepressant regimen.<sup>59</sup>

A clinician must also keep in mind that many atypical antipsychotic drugs are used today as adjunctive treatment for depression and can even be employed as stand-alone treatment,<sup>60</sup> in which case the potential for sex differences in either pharmacokinetics or pharmacodynamics must also be considered. In the use of atypical antipsychotics for psychotic disorders, sex dif-

ferences in efficacy have generally not been found, although this is an area that deserves further study.<sup>61,62</sup> Most of the literature regarding sex differences with antipsychotics relates to side effects experienced during treatment. There is general agreement in the literature on women's increased susceptibility to weight gain, diabetes, metabolic syndrome, and specific cardiovascular risks of antipsychotics compared with men.<sup>63,64</sup> Atypical antipsychotics can raise prolactin levels, resulting in more pronounced symptoms in women than men, including galactorrhea, atrophic changes in the urethra and vaginal mucosa, reduced vaginal lubrication, dyspareunia, decreased libido, ovarian dysfunction, infertility, oligomenorrhea, and amenorrhea.<sup>65</sup> Not all atypical antipsychotics produce the same prolactin-elevating effects. For example, in a study by Wu et al, ziprasidone was associated with greater changes in prolactin levels in women than olanzapine.<sup>66</sup> Hyperprolactinemia appears to be more common with conventional antipsychotics and risperidone than with clozapine, olanzapine, and quetiapine.<sup>67</sup> In a study by Findling et al of risperidone use in children and adolescents aged 5 to 15 years old, serum prolactin levels rose in the first months of treatment before decreasing by week 13. In females, elevated prolactin levels were associated with galactorrhea, menstrual disturbances, and decreases in bone marrow density.<sup>68</sup> Amisulpride, an atypical antipsychotic that has been used to treat dysthymia, appears to elevate plasma prolactin to a greater degree than other atypicals, which can lead to galactorrhea, gynecomastia, and sexual dysfunction.<sup>69</sup>

## Pharmacokinetic differences

Different pharmacokinetic profiles exist between men and women for several antidepressants. Possible sources of these differences include differences in body weight, volume of plasma, gastric emptying and acid production, splanchnic blood flow, plasma protein levels, enzyme activity, as well as drug transport and clearance rate differences between sexes. Higher plasma levels<sup>39,70</sup> and lower clearance of TCAs have been found in females.<sup>71</sup> The higher percentage of adipose tissue and body fat in women than in men may be a source of these differences. Due to their lipophilic nature, antidepressants have an affinity for adipose tissue, often producing greater drug distribution in women.<sup>72,73</sup> Women also typically have lower gastric acid secretion and slower

stomach emptying than men. Gastric motility is often slowed in the presence of female sex hormones, decreasing the clearance of antidepressants.<sup>37,74</sup>

The complexity of determining sex effects is further highlighted by similar studies of the same antidepressant that utilized different study methodology. Unterecker et al examined a large therapeutic drug-monitoring database to determine the influence of sex on serum levels of venlafaxine and its metabolite *O*-desmethylvenlafaxine in patients treated with venlafaxine under naturalistic conditions. They found that women had about 30% higher dose-corrected serum levels of venlafaxine and *O*-desmethylvenlafaxine than men ( $P < 0.01$ ).<sup>75</sup> Despite this finding, the clinical report by Kornstein et al found no sex difference between males and females treated with venlafaxine.<sup>54</sup> Another cross-sectional study of a large therapeutic drug-monitoring database looked at sex differences in venlafaxine treatment given to elderly patients versus their younger counterparts, and found that the difference between age groups was independent of sex.<sup>76</sup>

Another factor to bear in mind is that antidepressants are noted to cause weight gain, which is variable between men and women. This is important because changing the weight gain and distribution of fat can affect the pharmacokinetics of the antidepressant drugs being administered. Noordam et al examined the association between antidepressant use and change in body mass index from the pharmacy records of 7269 participants and found weight gain was observed only in women (not men) who had been treated for at least 90 days with SSRIs.<sup>77</sup>

The enzyme superfamily cytochrome P450 (CYP450) is a major drug-metabolizing pathway in humans. Several CYP450 variants show sex differences that may affect exposure and pharmacokinetic profiles for antidepressants. Cytochrome P450 3A4 (CYP3A4) is a highly expressed liver enzyme that helps metabolize many drugs, including several SSRIs (sertraline, citalopram, fluoxetine, escitalopram, etc) and TCAs (amitriptyline, imipramine, clomipramine, etc). Drug substrates of CYP3A4 often clear faster in women than in men,<sup>78</sup> potentially caused by increased CYP3A4 enzymatic activity in females compared with males.<sup>79,80</sup> Contrary to this, drug substrates of cytochrome P450 2D6 (CYP2D6), a major metabolizer of xenobiotics, including desipramine and mirtazapine,<sup>81,82</sup> often clear faster in males than females.<sup>83</sup> Likewise, cytochrome P450 1A2

(CYP1A2) substrates have been found to clear faster in males than females,<sup>84-86</sup> although this has been disputed.<sup>87</sup> CYP1A2 may metabolize escitalopram to *S*-desmethylcitalopram and *S*-didesmethylcitalopram.<sup>88</sup> Also, a study found that race/ethnic differences in cytochrome P450 2B6 (CYP2B6) genotype and phenotype were observed only in women.<sup>89</sup> CYP2B6 is important for the metabolism of bupropion to its active metabolite hydroxybupropion.

The task of deconstructing how sex-based differences in metabolic enzymes affect the breakdown and distribution of antidepressants is confounded by the many classes of antidepressants, each affected by different enzymes. A complete picture of this interaction may require knowledge of the class and structure of each antidepressant, as well as the duration and repetition of exposure, and even concomitant medications.

## Adherence differences

Some studies have also found significant sex differences noted in adherence to antidepressant treatment. Adherence is defined as compliance with dosage and regimen as prescribed for a duration considered sufficiently adequate for therapeutic response. A historical cohort study of 310 994 individuals who filled antidepressant prescriptions during a 4-year period found adherence was significantly higher for males aged 20 to 40 years than for females of that age, but this relationship reversed later in life for those aged 50 to 70 years.<sup>90</sup> A historic cohort study of three Italian local health units of 88 755 patients with a prescription for antidepressants found that female sex was a predictor of better adherence.<sup>91</sup> On the other hand, a sample of 3684 patients with long-term prescription of antidepressants found compliance rates across sexes were similar, with 21.4% compliance for males and 22.4% compliance for females.<sup>92</sup>

## Female reproductive hormones

Estrogen is believed to be involved in both the pathogenesis of depression and the effectiveness of antidepressants. In vitro studies have shown that estrogen facilitates the formation of dendritic spines and also influences neurotrophic factors.<sup>93</sup> Progesterone has also been shown to decrease gastric emptying, which has the potential to modify an antidepressant's phar-

# Pharmacological aspects

macokinetics.<sup>73</sup> Estrogen interacts with the serotonergic system, which is the target of SSRIs. In a challenge study employing the serotonin agonist meta-chlorophenylpiperazine, cortisol and prolactin responses were increased in postmenopausal women who were placed on 1 month of estrogen replacement therapy.<sup>94</sup> Eighty-six depressed male and premenopausal females (18 to 40 years old) were given the SSRI citalopram and the SNRI reboxetine in a blinded, 8-week clinical trial. Premenopausal females were shown to have a better response than males to serotonergic antidepressants, implying that female hormones may improve the efficacy of antidepressants.<sup>35</sup>

These observations were corroborated by studies in depressed postmenopausal women receiving estrogen replacement therapy combined with an SSRI. Depressed postmenopausal females on supplemental estrogen plus SSRIs demonstrated improved response compared with depressed postmenopausal females who received only an SSRI.<sup>95</sup> An open-label, naturalistic, 6-week study examined how premenopausal and postmenopausal females with depression respond to several antidepressants, including TCAs, SNRIs, and SSRIs. This study demonstrated that postmenopausal females had a poorer response to antidepressants than premenopausal females. This inferior response was associated with elevated follicle-stimulating hormone levels.<sup>96</sup>

Naturalistic studies of antidepressants in menopause also support the hypothesis that reproductive hormones may improve the efficacy of antidepressants. One naturalistic study examined 242 females (95 postmenopausal) and 59 males with depression, who began treatment using an SSRI (citalopram, fluoxetine, paroxetine, or sertraline) at primary care centers during a 6-month period. Menopause appeared to produce a poorer response to SSRI treatment in depressed females.<sup>52</sup> Another study looked at 115 depressed female outpatients (separated by menopause status) and 86 age-matched male outpatients who underwent an 8-week treatment taking either the SSRI nefazodone or venlafaxine. Premenopausal females demonstrated a better response to SSRI treatment than postmenopausal females.<sup>97</sup>

Harvey et al reasoned that acute worsening of depression would be found more frequently in females who were postmenopausal than in both premenopausal females and males.<sup>98</sup> However, after reviewing HAM-D scores in 554 patients over 3582 clinic visits, these investigators found the opposite was true—more episodes

of worsening depression occurred in premenopausal females and males than in postmenopausal females. Complicating matters further, a secondary analysis by Kornstein et al of a 10-week double-blind study of 670 female and 377 male outpatients with recurrent MDD found no difference between venlafaxine extended release or fluoxetine on the basis of menopausal status in the treatment of major depression.<sup>54</sup>

Even estrogen's mechanism of action in ameliorating depression is unclear. For example, estrogen may play a role as a mood enhancer, separate from any specific role in enhancing antidepressant efficacy. Supporting this notion, estrogen given to perimenopausal females who were not taking antidepressants still proved to be effective at treating depression.<sup>99</sup> In addition, stopping estrogen replacement therapy in females over 40 years old who had previous recurrent episodes of depression rapidly induced a new depressive episode.<sup>100</sup> In contrast, several studies have found no elevated risk for depression in females during their postmenopausal period, when reproductive hormones such as estrogen decrease dramatically.<sup>101,102</sup> Another study found that estrogen alone did not relieve depression in most postmenopausal females.<sup>103</sup>

Low luteinizing hormone (LH) levels may also predict improved response to antidepressant therapy in postmenopausal females.<sup>104</sup> Levels of serotonin appear to vary inversely with LH levels.<sup>105</sup> Therefore, lower LH levels suggest higher baseline serotonin levels for antidepressants to work upon. A correlation has been shown between lower LH levels and hypothalamic-pituitary-adrenal (HPA) axis hyperactivity.<sup>106,107</sup> Normal HPA activity has been found to be disrupted in MDD,<sup>108</sup> and antidepressants have been shown to reduce HPA activity. Low LH levels may therefore indicate a hyperactive HPA axis and identify potentially good responders to antidepressant treatment.<sup>109,110</sup>

In young females, the menstrual cycle itself may also modulate the effectiveness of antidepressants. The menstrual cycle may alter gastric contractions and fluid retention, resulting in a dilution of antidepressant levels in plasma.<sup>73</sup>

## Conclusion

Although the evidence is not conclusive, there are two observations that may be made at this time. First, a number of studies suggest that females respond better



to serotonergic antidepressants than males. Secondly, postmenopausal females appear to have a diminished response to antidepressants compared with younger females. All the issues reviewed in this paper are thought to play a role in producing sex-specific differences in response to antidepressant therapy, although the discrete role of any one variable is far from clear. In those situations where differences in response related to sex have been suggested, the magnitude of that difference is of questionable clinical importance. Published studies on the same class of antidepressants have produced conflicting results regarding sex effects. Conflicting results may stem from various sources, including study-related methodological differences and variance in the measurement of treatment responses.

Clearer data exists regarding sex differences in antidepressant metabolism, related to absorption, distribution, and elimination. Sex-specific variance has been identified in numerous biological functions influencing pharmacokinetic determinations, including plasma levels, production of gastric acid, gastric emptying times, lev-

els of plasma protein, enzyme activity, and drug transport and clearance rates. However, it is not clear that such differences translate into clinical practice guidelines, as our earlier example of venlafaxine indicates.

A better understanding of the interactions between these many complex systems is probably required to understand sex differences in depression prevalence and treatment response. At the present time, no specific guidelines can be offered, thus the clinician must remain vigilant to the possibility of sex effects either on the levels of exposure achieved with therapeutic dosing or on the clinical efficacy when treating depressed patients. As is true across many types of pharmacotherapy for psychiatric disorders, available guidance provides only a framework for the use of antidepressant pharmacotherapy for the practicing clinician rather than a codified set of instructions applicable to practice. □

**Acknowledgments/Conflict of Interest:** The authors acknowledge Andrew Kuhlman for his assistance in compiling, writing, and editing this manuscript. The authors state no conflict of interest in the creation of this manuscript.

## REFERENCES

1. Sramek JJ, Cutler NR. The impact of gender on antidepressants. *Curr Top Behav Neurosci*. 2011;8:231-249.
2. Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. *Arch Gen Psychiatry*. 1977;34(1):98-111.
3. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives. *J Affect Disord*. 1993;29(2-3):77-84.
4. Rapaport MH, Thompson PM, Kelsoe JR Jr, Golshan S, Judd LL, Gillin JC. Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. *J Clin Psychiatry*. 1995;56(2):67-72.
5. Lucht M, Schaub RT, Meyer C, et al. Gender differences in unipolar depression: a general population survey of adults between age 18 to 64 of German nationality. *J Affect Disord*. 2003;77(3):203-211.
6. Leibenluft E, Hardin T, Rosenthal N. Gender differences in seasonal affective disorder. *Depression*. 1995;3(1-2):13-19.
7. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. *J Affect Disord*. 1993;29(2-3):85-96.
8. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry*. 1994;51(1):8-19.
9. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in chronic major and double depression. *J Affect Disord*. 2000;60(1):1-11.
10. Frank E, Carpenter LL, Kupfer DJ. Sex differences in recurrent depression: are there any that are significant? *Am J Psychiatry*. 1988;145(1):41-45.
11. Young MA, Scheftner WA, Fawcett J, Klerman GL. Gender differences in the clinical features of unipolar major depressive disorder. *J Nerv Ment Dis*. 1990;178(3):200-203.
12. Angst J, Dobler-Mikola A. Do the diagnostic criteria determine the sex ratio in depression? *J Affect Disord*. 1984;7(3-4):189-198.
13. Williams JB, Spitzer RL, Linzer M, et al. Gender differences in depression in primary care. *Am J Obstet Gynecol*. 1995;173(2):654-659.
14. Nolen-Hoeksema S. *Sex Differences in Depression*. Stanford, California: Stanford University Press; 1990.
15. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. *Int Rev Psychiatry*. 2003;15(1-2):74-83.
16. Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. *Arch Gen Psychiatry*. 2003;60(1):29-36.
17. Young EA, Midgley AR, Carlson NE, Brown MB. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. *Arch Gen Psychiatry*. 2000;57(12):1157-1162.
18. Amin Z, Canli T, Epperson CN. Effect of estrogen-serotonin interactions on mood and cognition. *Behav Cogn Neurosci Rev*. 2005;4(1):43-58.
19. Moreno FA, McGahuey CA, Freeman MP, Delgado PL. Sex differences in depressive response during monoamine depletions in remitted depressive subjects. *J Clin Psychiatry*. 2006;67(10):1618-1623.
20. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. *Proc Natl Acad Sci U S A*. 1997;94(10):5308-5313.
21. Young SN, Gauthier S, Anderson GM, Purdy WC. Tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human cerebrospinal fluid: interrelationships and the influence of age, sex, epilepsy and anticonvulsant drugs. *J Neurol Neurosurg Psychiatry*. 1980;43(5):438-445.
22. Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in <sup>123</sup>I-β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. *Synapse*. 2001;41(4):275-284.
23. Cidis Meltzer C, Drevets WC, Price JC, et al. Gender-specific aging effects on the serotonin 1A receptor. *Brain Res*. 2001;895(1-2):9-17.
24. Legato MJ. Gender-specific physiology: how real is it? How important is it? *Int J Fertil Womens Med*. 1997;42(1):19-29.
25. Veral A, Alper G, Mentis G, Ersoz B. Age and sex related alterations in serum and platelet monoamine oxidase. *Eur J Clin Chem Clin Biochem*. 1997;35(4):265-268.

# Pharmacological aspects

26. Laakso A, Vilkmann H, Bergman J, et al. Sex differences in striatal pre-synaptic dopamine synthesis capacity in healthy subjects. *Biol Psychiatry*. 2002;52(7):759-763.
27. Shimizu H, Bray GA. Effects of castration, estrogen replacement and estrus cycle on monoamine metabolism in the nucleus accumbens, measured by microdialysis. *Brain Res*. 1993;621(2):200-206.
28. Xiao L, Becker JB. Quantitative microdialysis determination of extracellular striatal dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. *Neurosci Lett*. 1994;180(2):155-158.
29. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. *Biol Psychiatry*. 2006;59(10):966-974.
30. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. *J Clin Psychiatry*. 1999;60(8):508-518.
31. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. *Am J Psychiatry*. 2000;157(9):1445-1452.
32. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. *Eur Neuropsychopharmacol*. 2001;11(3):227-232.
33. Quitkin FM, Stewart JW, McGrath PJ, et al. Are there differences between women's and men's antidepressant responses? *Am J Psychiatry*. 2002;159(11):1848-1854.
34. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. *J Clin Psychopharmacol*. 2005;25(4):318-324.
35. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. *J Affect Disord*. 2006;95(1-3):119-123.
36. Naito S, Sato K, Yoshida K, et al. Gender differences in the clinical effects of fluvoxamine and milnacipin in Japanese major depressive patients. *Psychiatry Clin Neurosci*. 2007;61(4):421-427.
37. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR\*D report. *J Psychiatr Res*. 2009;43(5):503-511.
38. Yang SJ, Kim SY, Stewart R, et al. Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study. *Psychiatry Res*. 2011;189(1):82-90.
39. Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depression: when does it matter? In: Jensvold MF, Halbreich U, Hamilton JA, eds. *Psychopharmacology and Women: Sex, Gender, and Hormones*. Washington, DC: American Psychiatric Press, Inc; 1996:241-257.
40. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. *Br J Psychiatry*. 1993;162:175-182.
41. Raskin A. Age-sex differences in response to antidepressant drugs. *J Nerv Ment Dis*. 1974;159(2):120-130.
42. Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with non-melancholic depressive disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004;28(1):57-65.
43. Quitkin FM, Stewart JW, McGrath PJ. Gender differences in treatment response. *Am J Psychiatry*. 2001;158(9):1531-1533.
44. Vermeiden M, van den Broek WW, Mulder PG, Birkenhager TK. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. *J Psychopharmacol*. 2010;24(4):497-502.
45. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. *Psychiatry Res*. 1986;17(2):87-95.
46. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. *Am J Psychiatry*. 1991;148(7):910-916.
47. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. *J Clin Psychiatry*. 2001;62(11):869-877.
48. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Sorensen P; Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants? *Am J Psychiatry*. 2003;160(9):1643-1650.
49. Parker G, Parker K, Austin MP, Mitchell P, Brotchie H. Gender differences in response to differing antidepressant drug classes: two negative studies. *Psychol Med*. 2003;33(8):1473-1477.
50. Wohlfarth T, Storum JG, Elferink AJ, van Zwieten BJ, Fouwels A, van den Brink W. Response to tricyclic antidepressants: independent of gender? *Am J Psychiatry*. 2004;161(2):370-372.
51. Thiels C, Linden M, Grieger F, Leonard J. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. *Int Clin Psychopharmacol*. 2005;20(1):1-7.
52. Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? *J Affect Disord*. 2006;93(1-3):53-60.
53. Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. *J Clin Psychopharmacol*. 2010;30(3):294-299.
54. Kornstein SG, Pedersen RD, Holland PJ, et al. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. *J Clin Psychiatry*. 2014;75(1):62-68.
55. Cuijpers P, Weitz E, Twisk E, et al. Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. *Depress Anxiety*. 2014;31(11):941-951.
56. Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. *Ann Pharmacother*. 2000;34(1):80-88.
57. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. *Am J Psychiatry*. 1997;154(12):1757-1759.
58. Sramek JJ, Frackiewicz EJ. Effect of sex on psychopharmacology of antidepressants. In: Lewis-Hall F, Williams TS, Panetta JA, Herrera JM, eds. *Psychiatric Illness in Women: Emerging Treatments and Research*. Washington DC: American Psychiatric Publishing, Inc; 2002:113-131.
59. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. *Int J Psychiatry Med*. 1995;25(3):239-248.
60. Suppes T, Silva R, Cucchiari J, et al. Lurasidone for the treatment of Major Depressive Disorder With Mixed Features: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2016;173(4):400-407.
61. Ceskova E, Prikrly R. Importance of gender in the treatment of schizophrenia. *Prim Care Companion CNS Disord*. 2012;14(6). doi:10.4088/PCC.12m01407.
62. Ceskova E, Prikrly R, Libiger J, Svancara J, Jarkovsky J. Gender differences in the treatment of first-episode schizophrenia: results from the European First Episode Schizophrenia Trial. *Schizophr Res*. 2015;169(1-3):303-307.
63. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. *Schizophr Bull*. 2009;35(5):937-948.
64. Riordan HJ, Antonini P, Murphy MF. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. *Am Health Drug Benefits*. 2011;4(5):292-302.
65. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. *J Clin Psychopharmacol*. 2007;27(6):639-661.
66. Wu XL, Wang JH, Hu SH, Tao J. Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). *East Asian Arch Psychiatry*. 2012;22(1):7-11.
67. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. *Psychoneuroendocrinology*. 2003;28(suppl 2):69-82.
68. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. *J Clin Psychiatry*. 2003;64(11):1362-1369.
69. Raj R, Sidhu BS. Hyperprolactinaemia with amisulpride. *Indian J Psychiatry*. 2008;50(1):54-56.

70. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. *J Clin Psychiatry*. 1985;46(7):276-277.
71. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. *Clin Pharmacokinet*. 1990;19(3):241-255.
72. Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? *J Clin Psychiatry*. 2002;63(7):610-615.
73. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. *Am J Psychiatry*. 1992;149(5):587-595.
74. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. *Gastroenterology*. 1989;96(1):11-17.
75. Unterecker S, Hiemke C, Greiner C, et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. *Pharmacopsychiatry*. 2012;45(6):229-235.
76. Sigurdsson HP, Hefner G, Ben-Omar N, et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. *J Neural Transm (Vienna)*. 2015;122(5):721-729.
77. Noordam R, Aarts N, Tiemeier H, Hofman A, Stricker BH, Visser LE. Sex-specific association between antidepressant use and body weight in a population-based study in older adults. *J Clin Psychiatry*. 2015;76(6):e745-751.
78. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? *Clin Pharmacokinet*. 2002;41(5):329-342.
79. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. *Biochem Pharmacol*. 1992;44(2):275-283.
80. Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. *Eur J Drug Metab Pharmacokinet*. 2001;26(3):193-200.
81. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. *J Pharmacol Exp Ther*. 1985;232(1):183-188.
82. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. *Clin Pharmacokinet*. 2000;38(6):461-474.
83. Labbe L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. *Pharmacogenetics*. 2000;10(5):425-438.
84. Ou-Yang DS, Huang SL, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. *Br J Clin Pharmacol*. 2000;49(2):145-151.
85. Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. *J Clin Psychopharmacol*. 1991;11(5):296-301.
86. Bruno R, Vivier N, Montay G, et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. *Clin Pharmacol Ther*. 1997;62(5):518-526.
87. Nafziger AN, Bertino JS, Jr. Sex-related differences in theophylline pharmacokinetics. *Eur J Clin Pharmacol*. 1989;37(1):97-100.
88. Kuo HW, Liu SC, Tsou HH, et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. *Pharmacogenomics*. 2013;14(10):1191-1201.
89. Ilic K, Hawke RL, Thirumaran RK, et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. *Drug Metab Dispos*. 2013;41(3):575-581.
90. Krivoy A, Balicer RD, Feldman B, et al. The impact of age and gender on adherence to antidepressants: a 4-year population-based cohort study. *Psychopharmacology (Berl)*. 2015;232(18):3385-3390.
91. Degli Esposti L, Piccinni C, Sangiorgi D, Fagiolini A, Buda S. Patterns of antidepressant use in Italy: therapy duration, adherence and switching. *Clin Drug Investig*. 2015;35(11):735-742.
92. Serna MC, Real J, Cruz I, Galvan L, Martin E. Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance. *BMC Public Health*. 2015;15:1184.
93. Bryant DN, Sheldahl LC, Marriott LK, Shapiro RA, Dorsa DM. Multiple pathways transmit neuroprotective effects of gonadal steroids. *Endocrine*. 2006;29(2):199-207.
94. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in postmenopausal women. *Biol Psychiatry*. 1995;37(7):434-441.
95. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. *Am J Geriatr Psychiatry*. 1997;5(2):97-106.
96. Pae CU, Mandelli L, Kim TS, et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. *Biomed Pharmacother*. 2009;63(3):228-235.
97. Grigoriadis S, Kennedy SH, Bagby RM. A comparison of antidepressant response in younger and older women. *J Clin Psychopharmacol*. 2003;23(4):405-407.
98. Harvey AT, Silkey BS, Kornstein SG, Clary CM. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. *J Clin Psychiatry*. 2007;68(6):951-958.
99. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. *Arch Gen Psychiatry*. 2001;58(6):529-534.
100. Stewart DE, Rolfe DE, Robertson E. Depression, estrogen, and the Women's Health Initiative. *Psychosomatics*. 2004;45(5):445-447.
101. McKinlay JB, McKinlay SM, Brambilla DJ. Health status and utilization behavior associated with menopause. *Am J Epidemiol*. 1987;125(1):110-121.
102. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. *Ann Epidemiol*. 1994;4(3):214-220.
103. Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. *Biol Psychiatry*. 2004;55(4):406-412.
104. Zanardi R, Rossini D, Magri L, Malaguti A, Colombo C, Smeraldi E. Response to SSRIs and role of the hormonal therapy in post-menopausal depression. *Eur Neuropsychopharmacol*. 2007;17(6-7):400-405.
105. Carretti N, Florio P, Bertolin A, Costa CV, Allegri G, Zilli G. Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization. *Hum Reprod*. 2005;20(6):1548-1553.
106. Vadakkadath Meethal S, Atwood CS. The role of hypothalamic-pituitary-gonadal hormones in the normal structure and functioning of the brain. *Cell Mol Life Sci*. 2005;62(3):257-270.
107. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. *Ageing Res Rev*. 2005;4(2):141-194.
108. Pariante CM. Depression, stress and the adrenal axis. *J Neuroendocrinol*. 2003;15(8):811-812.
109. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocr Rev*. 1996;17(2):187-205.
110. Holsboer F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology*. 2000;23(5):477-501.